Cargando…

Type B adverse drug reactions reported by an immunoallergology department

OBJECTIVE: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC). METHODS: An observational, descriptive and retrospective study was conducted, based in a spontane...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Maria J., Herdeiro, Maria T., Polónia, Jorge J., Ribeiro-Vaz, Inês, Botelho, Cármen, Castro, Eunice, Cernadas, Josefina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881478/
https://www.ncbi.nlm.nih.gov/pubmed/29619134
http://dx.doi.org/10.18549/PharmPract.2018.01.1070
_version_ 1783311328143736832
author Costa, Maria J.
Herdeiro, Maria T.
Polónia, Jorge J.
Ribeiro-Vaz, Inês
Botelho, Cármen
Castro, Eunice
Cernadas, Josefina
author_facet Costa, Maria J.
Herdeiro, Maria T.
Polónia, Jorge J.
Ribeiro-Vaz, Inês
Botelho, Cármen
Castro, Eunice
Cernadas, Josefina
author_sort Costa, Maria J.
collection PubMed
description OBJECTIVE: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC). METHODS: An observational, descriptive and retrospective study was conducted, based in a spontaneous report system. Participants were all the patients from the IAD, with suspected ADR, reported to NPC by specialists after the study was completed. RESULTS: Studied population had a median age of 41 years, with the predominance of the female gender (73.2%). Allergic rhinitis and asthma were the most frequent comorbidities. All studied ADR were type B, 89.6% were serious, 86.4% unexpected and 2.6% associated with drugs that presented less than 2 years in the market. The most represented drug classes were the non-steroidal anti-inflammatory drugs (NSAIDs) (52.6%) and antibiotics (25.2%). Skin symptoms represented 61.2% of the reported complaints. About 52.9% of these ADR occurred in less than one hour after intake. The most frequent ADR treatment at the time of the reaction was drug interruption (86.2%), followed by the prescription of anti-histamines (42.2%). CONCLUSIONS: Reported ADR to NPC by the Drug Alert Unit were mainly serious, unexpected, associated with NSAIDs and antibiotics and related with marketing authorization medicines older than two years. These results could be very useful to develop strategies to prevent the clinical and economic consequences of ADR.
format Online
Article
Text
id pubmed-5881478
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-58814782018-04-04 Type B adverse drug reactions reported by an immunoallergology department Costa, Maria J. Herdeiro, Maria T. Polónia, Jorge J. Ribeiro-Vaz, Inês Botelho, Cármen Castro, Eunice Cernadas, Josefina Pharm Pract (Granada) Original Research OBJECTIVE: Characterization of the adverse drug reactions (ADR) reported by the immunoallergology department (IAD), Centro Hospitalar de São João (Porto), to the Northern Pharmacovigilance Centre (NPC). METHODS: An observational, descriptive and retrospective study was conducted, based in a spontaneous report system. Participants were all the patients from the IAD, with suspected ADR, reported to NPC by specialists after the study was completed. RESULTS: Studied population had a median age of 41 years, with the predominance of the female gender (73.2%). Allergic rhinitis and asthma were the most frequent comorbidities. All studied ADR were type B, 89.6% were serious, 86.4% unexpected and 2.6% associated with drugs that presented less than 2 years in the market. The most represented drug classes were the non-steroidal anti-inflammatory drugs (NSAIDs) (52.6%) and antibiotics (25.2%). Skin symptoms represented 61.2% of the reported complaints. About 52.9% of these ADR occurred in less than one hour after intake. The most frequent ADR treatment at the time of the reaction was drug interruption (86.2%), followed by the prescription of anti-histamines (42.2%). CONCLUSIONS: Reported ADR to NPC by the Drug Alert Unit were mainly serious, unexpected, associated with NSAIDs and antibiotics and related with marketing authorization medicines older than two years. These results could be very useful to develop strategies to prevent the clinical and economic consequences of ADR. Centro de Investigaciones y Publicaciones Farmaceuticas 2018 2018-03-21 /pmc/articles/PMC5881478/ /pubmed/29619134 http://dx.doi.org/10.18549/PharmPract.2018.01.1070 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Costa, Maria J.
Herdeiro, Maria T.
Polónia, Jorge J.
Ribeiro-Vaz, Inês
Botelho, Cármen
Castro, Eunice
Cernadas, Josefina
Type B adverse drug reactions reported by an immunoallergology department
title Type B adverse drug reactions reported by an immunoallergology department
title_full Type B adverse drug reactions reported by an immunoallergology department
title_fullStr Type B adverse drug reactions reported by an immunoallergology department
title_full_unstemmed Type B adverse drug reactions reported by an immunoallergology department
title_short Type B adverse drug reactions reported by an immunoallergology department
title_sort type b adverse drug reactions reported by an immunoallergology department
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881478/
https://www.ncbi.nlm.nih.gov/pubmed/29619134
http://dx.doi.org/10.18549/PharmPract.2018.01.1070
work_keys_str_mv AT costamariaj typebadversedrugreactionsreportedbyanimmunoallergologydepartment
AT herdeiromariat typebadversedrugreactionsreportedbyanimmunoallergologydepartment
AT poloniajorgej typebadversedrugreactionsreportedbyanimmunoallergologydepartment
AT ribeirovazines typebadversedrugreactionsreportedbyanimmunoallergologydepartment
AT botelhocarmen typebadversedrugreactionsreportedbyanimmunoallergologydepartment
AT castroeunice typebadversedrugreactionsreportedbyanimmunoallergologydepartment
AT cernadasjosefina typebadversedrugreactionsreportedbyanimmunoallergologydepartment